Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another poor review, Causes Pain
Condition: Irritable Bowel Syndrome with Constipation
7/29/2014 1:38:53 PM
.
Reviewer: durk, 65-74 Male on Treatment for less than 1 month (Patient)
Effectiveness
Current Rating: 5
.
Ease of Use
Current Rating: 5
.
Satisfaction
Current Rating: 1
.
Comment:
cannot take abdominal pain. but was effective
From someone who actually used it, from WebMd
Condition: Irritable Bowel Syndrome with Constipation
8/27/2014 9:11:22 PM
.
Reviewer: Male on Treatment for 1 to 6 months (Patient)
Effectiveness
Current Rating: 2
.
Ease of Use
Current Rating: 4
.
Satisfaction
Current Rating: 1
.
Comment:
Have been taking Linzess for close to 6 months. It worked somewhat OK for the first few months, and then just quit working altogether. It never did produce diarrhea like most people have reported. About a month ago, I started having bodywide joint and muscle aches. I stopped the Linzess and the aches and pains went away in a few days. Not sure if this is a side effect. I think I'll stick with MiraLax. It's the only thing that works for me and is a heck of a lot cheaper.
Hide Full Comment
High rate of poops as side effect. So, you either have to wear a diaper or ruin your best suit
compare the 1 yr charts of IRWD and SGYP.
I like the IRWD "trend" better :)
RED, DIVING, 2.5 % today
The selloff slide continues
Brutal day , for SGYP as well (-2.8%), agree. Looks like the shorts are hard at work again...
Almost broke UNDER 13 today, the trend is your friend
not gonna happen. the option market should give you a clue...but apparently the hay's not hanging low enough yet for this horse to get it ...
http://finance.yahoo.com/news/trade-sees-ironwood-solid-ground-160737834.html
Red at 10 AM, Red at 2 PM, Fact based
"deteriorating net income"
Getting closer to 8, that's where I will get back in
Red Again!, 8/19, down 25 cents, slide continues
Fact: 16 in June, 13 in August, which way is the pps trending?
Actually, the SGYP picture is the really grim one - stock price ~40% down since March, continual dilution, only 2Q of operating expenses left in the bank, years away from a product on the market (if ever), no interest in buyout / partnership on the horizon --- LOL how much more grim can it get ??
read the JP Morgan article again:
http://seekingalpha.com/article/2222433-j-p-morgans-geoff-meacham-plucks-biotechs-with-upside-from-a-down-market
even if they would ever make it to the market (2017 at the earliest), which I doubt, the only way they could ever compete with IRWD is on price (says JP Morgan).
If you look at the structure/complexity/size of both synthetic peptides, and all natural amino acid building blocks in both (plecanatide + linaclotide), an educated guess would probably place the drug manufacturing costs in the same ball park for both companies.
Since the Synergy drug seems to require at least 10x (maybe even more) the dose to touch linaclotide in terms of efficacy, the chances of Synergy to compete in terms of price, in my opinion, are zero, nada, none.
no wonder no one wants to buy them...
200 million in debt, w/no refills that is a lot of new prescriptions. Market saturation, and then being overtaken by "blockbuster" best in class plecanatide, is a grim picture
IRWD debt management criticized. This is important when you have close to 200 million in debt, and patients are not refilling their prescriptions
More bad news from "The Street" Cramer's place:
The Street Quant Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk.
Highlights from the ratings report include:
? Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, IRONWOOD PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
? The debt-to-equity ratio of 1.26 is relatively high when compared with the industry average, suggesting a need for better debt level management. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 7.36, which shows the ability to cover short-term cash needs.
? The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 7.3% when compared to the same quarter one year prior, going from -$65.15 million to -$60.36 million.
? The revenue fell significantly faster than the industry average of 36.4%. Since the same quarter one year prior, revenues fell by 29.2%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share
...you forgot to add "in my personal opinion"
...how about the one JP Morgan voiced three months ago taking into account the Synergy trial results to date?
I'll take my chances with JP Morgan, thank you very much.
(quote): "...Synergy Pharmaceuticals Inc.is starting two Phase 3 trials with its constipation drug candidate, plecanatide, which would be a competitor to Linzess. Does that put pressure on Ironwood?
GM: Our view is that it doesn't, for a couple of reasons. The first is that the theoretical differentiation for the Synergy drug was that it would have a lower rate of diarrhea, which is one of the most common adverse events with Ironwood's Linzess. The efficacy was presumed to be equal. What we know now, from Phase 2/3 trials, some released last year, is that for diarrhea, plecanatide looks largely similar. It is not differentiated in that respect. Its efficacy is not exactly equal. It's going to be difficult to market a drug like plecanatide in a primary care setting when it isn't any different from Linzess. ..."
quote from:
http://www.hispanicbusiness.com/2014/5/16/j_p_morgan_s_geoff_meacham.htm
What does 'the street' say about Synergy, with zero income, cash running out in 2 quarters, vulnerable IP position & no partnership on the horizon ??
Just curious ..,
"and the juice runs down my leg" from an actual user of the drug, not from a pumper queen, who has never taken it, but should
renamed from IRWD to DWD, diarrhea-wood. Too bad it doesn't help with ED, it could be called diarrhea-woody, lol
"The Street" says "deteriorating net income" from their article on diarrhea-wood
actually, I was correcting your lies remember LOL
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105337674
why don't we compare notes towards the end of the year, see how things play out for IRWD, and if SGYP actually manages to stay afloat, despite their desperate financial situation...
Uh, new AGA guidelines for IBS treatment were over your head, dude ?
and the UHC step edit coverage that favors the IRWD drug over Amitiza escaped your notice as well?
They have revenue & a product on the market. Synergy has no revenue, is years away from having a product on the market, and has only 2 Quarters of Operating expenses left in the bank , so says Cantor Fitzgerald; you posted it yourself, remember ? And that would be 'superior' to IRWD how, exactly ??
From Web MD-Not good, the sheen is off the poop
A further look at Linzess on WebMD.com (by no means representative of all prescription users but good for some opinions nonetheless) shows user review ratings of 3.7/5 for effectiveness and 3.2/5 for satisfaction. Those ratings are quite misleading though. Read many of the comments and even people rating Linzess 4 or 5 often include comments talking about dealing with diarrhea or other pain. One user wrote:
My only advice is be sure in the beginning to take [Linzess] when you are going to be home so that you can see how the drug is going to work for you. I waited until a Sunday morning to take my first dose and I am glad I did! It was a rumbling tummy, I had a runny bowel movement and I had to go a few times. Good luck.
So, why is the net income deteriorating? The runs, and NO refills on the initial prescription. NO one wants brown juice running down their leg, it is embarrassing, so they would rather be "clogged" because no one notices that. FACT JACK
Wow, Look at This: Not Good at all, "deteriorating net income"
NEW YORK (TheStreet) -- Ironwood Pharmaceuticals (IRWD_) was falling -8.2% to $13.63 Tuesday after missing analysts estimates for earnings and revenue for the second quarter.
The company reported a loss of -38 cents a share for the second quarter, missing the Capital IQ Consensus Estimate of -36 cents a share by 2 cents. Revenue fell -29.2$ year-over-year to $6.84 million for the quarter. Analysts expected revenue of $15.75 million in the quarter.
The Street Ratings team rates IRONWOOD PHARMACEUTICALS INC as a Sell with a ratings score of D. The Street Ratings Team has this to say about their recommendation:
"We rate IRONWOOD PHARMACEUTICALS INC (IRWD) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its deteriorating net income."
Chemist, I don't read your posts, lies
So, don't waste your lies on me
I am here to inform the rest, save them from you
An Ironwood formulation patent that is expected to extend LINZESS® Patent Protection Through 2031 (see: http://news.ironwoodpharma.com/Press-Releases/Ironwood-Receives-Notice-of-Allowance-for-Methods-of-Use-Formulation-Patent-Expected-to-Extend-LINZE-f1.aspx)
has just been issued (Aug 15, 2014): http://www.4-traders.com/IRONWOOD-PHARMACEUTICALS-5933097/news/Ironwood-Pharmaceuticals--Forest-Laboratories-Holdings-Assigned-Patent-18907216/
Also, before you spread lies, it would behoove you well to read up on the company & the facts:
the brand is actually approaching profitability after only about 18 months (and there has never before been an example of a biotech successfully launching a primary care drug, so that alone is quite a feat)!
There is strong demand for Linzess(R): prescriptions jumped 36% from 1Q to 2Q 2014. With regard to refill rate: there is strong patient persistence, tracking 40-65% ahead of launch analogues, see the IRWD Q2 2014 Investor Update from Aug 4, 2014:
http://investor.ironwoodpharma.com/common/download/download.cfm?companyid=ABEA-45DU4J&fileid=773700&filekey=ca1eef29-983d-41ff-a376-c377e858a3a6&filename=IRWD_Q214.InvestorUpdate.pdf
if you haven't fallen off the learning curve completely & want to try to understand why the institutional ownership in IRWD is so high - this is a good starting point:
http://www.gastrojournal.org/article/S0016-5085(13)01529-1/pdf
you failed to read between the lines. nothing but a paid shill trying to keep up morale, since they're the ones having to sell all the SGYP shares to (try to) keep them afloat, remember?
and you keep forgetting : at an ever decreasing share price:
SGYP Mar 13, 2014: $6.07
this morning : $3.63 (-40%)
IRWD Mar 13, 2014: $12.74
today: $13.07 (+2.6%)
maybe you didn't pay attention ?
looks like Cantor Fitzgerald is slowly changing their tune. Formerly extremely bullish, even they acknowledge now that SGYP is going to run out of cash ~ EOY 2014 and admit that only a (highly speculative) M&A scenario justifies their price target, read their release again:
(quote): ..."We continue to view Synergy as a likely takeout candidate and base our PT on an M&A valuation. We reiterate our BUY rating but acknowledge that there is a temporary financing overhang on the stock since the company has approximately two quarters of cash remaining.”
riddle me this... - if they're so attractive, why has no buyer shown up yet ?? and since all the super data for the "best in class" drug has not attracted a buyer until now, why would one show up now 2Q before they run out of cash ?
here's a hint for the slow learner class (the one you're enrolled in, so pay attention !):
it's the SAME REASON why there isn't a single institutional investor with more than ~$18 million in Synergy, whereas the largest institutional investor in IRWD put ~$250 million on the table...
http://www.nasdaq.com/symbol/sgyp/institutional-holdings
http://www.nasdaq.com/symbol/irwd/institutional-holdings
IRWD, Lasyness, is not getting refilled, why $ down
Patients do not like the runs, and in case nobody has noticed, this share price is running down. Fact
Chemist, your angle is off: I must not understand what blockbuster status means
..and improved tolerability, can you help me with that angle too, what am I missing? Oh, right, you can't help me to understand
But, IRWD missing on earnings, and dropping again today, that everyone can see AND understand.
In a research report released today, Cantor Fitzgerald analyst Irina Rivkind maintained a Buy rating on Synergy Pharmaceuticals (SGYP), with a $11 price target. The report follows the company’s second-quarter results, which included an operational loss of $25.9M and loss per share of ($0.28), below FactSet consensus loss per share estimates of ($0.23).
Rivkind noted, “Higher-than-anticipated R&D contributed to this miss, due to the second Phase III launch for plecanatide in CIC in 2Q:14. We expect 2014 R&D expense to grow and believe that consensus earnings estimates are too optimistic. With the recent price increases in constipation drugs and higher promotional noise level, we think that Synergy’s Plecanatide will be poised to enter an attractive and well-developed market in late 2016 and should attain blockbuster status given its improved tolerability. We continue to view Synergy as a likely takeout candidate and base our PT on an M&A valuation. We reiterate our BUY rating but acknowledge that there is a temporary financing overhang on the stock since the company has approximately two quarters of cash remaining.”
amitiza reps whining about the new UHC step edit coverage ...writing's on the wall
(see also new AGA guidelines IBS treatment )
http://www.cafepharma.com/boards/showthread.php?t=562537
wait, watch & learn
again, I can explain it to you (from 50 different angles), but I can't UNDERSTAND it for you :)
SGYP Mar 13, 2014: $6.07
today : $3.53 (-42%)
IRWD Mar 13, 2014: $12.74
today: $13.40 (+1%)
'nuff said
Chemist, down 5% Again, Groundhog day
Best in class Plecanatide coming
how do you miss after the blitzkrieg advertising?
People get explosive diarrhea from this drug
missed is spelled "missed", also known as didn't meet, less than anticipated, and 'bigger' loss
SGYP 6 mo ago (Feb 6, 2014): $ 5.07
SGYP today (open on Aug 6, 2014): $ 3.61 (-29%)
IRWD 6 mo ago (Feb 6, 2014): $ 12.32
IRWD today (open on Aug 6, 2014): $ 13.60 (+10%)
which story creates value ?
what does the market think ?
2014 Q2 IRWD Earnings Call Transcript with Analysts Q/A session :
http://seekingalpha.com/article/2172563-ironwoods-ceo-discusses-q1-2014-results-earnings-call-transcript
yo, chemist, little drop (big) & (steep)
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
260
|
Created
|
06/22/11
|
Type
|
Free
|
Moderators |
http://www.ironwoodpharma.com/
http://finance.yahoo.com/q/ks?s=IRWD+Key+Statistics
Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in confirmatory Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on one Phase I pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. It was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Overview article on Linaclotide, the company's lead drug: http://en.wikipedia.org/wiki/Linaclotide
Updated IRWD short volume numbers (source: www.nasdaq.com)
Settlement Date Short Interest
11/28/2014 14,593,658
11/14/2014 14,892,420
10/31/2014 14,952,106
10/15/2014 16,259,737
9/30/2014 15,155,353
6/30/2014 13,498,802
3/31/2014 18,224,084
12/31/2013 22,378,583
Total outstanding shares: 120 million (as of 03/31/2014)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |